Statue in Vienna of Heracles battling the hydra
Biotech

The 'diabolical' molecule set to become biotech's next gold rush

Should medicines that lower Lp(a) reach their full potential, they could spark a craze rivaling obesity and even surpass the success of statins.
Darren Incorvaia Apr 9, 2026 8:00am
vault

Roche takes ‘leap of faith’ with bet on C4T’s protein degraders

Apr 9, 2026 7:00am
IPO initial public offering

Avalyn plans IPO to fund ph. 3 trials of inhaled lung drugs

Apr 9, 2026 4:13am
Bottle of glue

Gilead pays Kymera $45M for preclinical protein degrader

Apr 9, 2026 8:45am
Three darts hitting bullseye

CAR-T drives 3 autoimmune diseases into remission in one patient

Apr 9, 2026 11:00am
Signage for the Department of Health and Human Services HHS headquarters is seen on April 02 2025 in Washington DC
Favicon Fierce Healthcare

States' lawsuit against RFK Jr.'s HHS overhaul moves forward

Apr 9, 2026 7:30am
More News

Akari locks arms with WuXi XDC to develop and manufacture ADC

Apr 8, 2026 11:30am

Fierce Biotech Fundraising Tracker '26: Life Bio, Sidewinder & more

Apr 8, 2026 9:00am

Astellas, Dyno unearth $15M muscle disorder capsid

Apr 8, 2026 8:00am

After $2.1B Novo deal, Vivtex is just getting started

Apr 8, 2026 8:00am